Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma

BMC Cancer

Research

Junlin Shen¹  Jianbin Bi¹  Linhui Wang¹ 

[1] Department of Urology, China Medical University, The First Hospital of China Medical University, Shenyang, Liaoning, China;

关键词: Clear cell renal cell carcinoma;    Cuproptosis;    Computational biology;    Robust model;    Risk signature;    Immune microenvironment;    Drug sensitivity;   

DOI  :  10.1186/s12885-023-10639-2

 received in 2022-11-05, accepted in 2023-02-13,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundClear cell renal cell carcinoma (ccRCC) is common in urinary system tumors. Cuproptosis is a non-apoptotic cell death pathway. Copper binds to fatty acylated mitochondrial proteins and activates various forms of cell death. LncRNA LINC02154 is significantly highly expressed in cells and tissues of many types of tumors, and the risk signature of LINC02154 in some tumors has been validated for effectiveness.MethodsWe constructed a risk prognostic signature by obtaining differentially expressed long noncoding RNAs (lncRNAs) associated with ccRCC outcomes and cuproptosis from The Cancer Genome Atlas (TCGA). We used TCGA to construct training and testing sets to analyze the risk signature and the impact of LINC02154, and we performed relevant survival analyses. Tumor mutational burdens were analyzed in different LINC02154 expression groups and risk score groups. We next analyzed the immune microenvironment of LINC20154. We performed LINC20154-related drug sensitivity analyses. We also investigated the cellular function of LINC02154 in the ACHN cell line and performed CCK-8 assay, EdU, wound-healing assay, and Transwell assay. The essential genes FDX1 and DLST of cuproptosis were detected by western blot.ResultsWe demonstrated that LINC02154’s impact on outcomes was statistically significant. We also demonstrated the association of different ages, genders, stages, and grades with LINC02154 and risk models. The results showed a significant difference in tumor mutation burden between the groups, which was closely related to clinical prognosis. We found differences in immune cells among groups with different levels of LINC02154 expression and significant differences in immune function, immunotherapeutic positive markers, and critical steps of the immune cycle. The sensitivity analysis showed that differential expression of LINC02154 discriminated between sensitivity to axitinib, doxorubicin, gemcitabine, pazopanib, sorafenib, sunitinib, and temsirolimus. This difference was also present in the high-risk group and low-risk group. We demonstrated that the proliferation and migration of t ACHN cells in the LINC02154 knockdown group were inhibited. The western blot results showed that the knockdown of LINC02154 significantly affected the expression of FDX1 and DLST, critical genes of cuproptosis.ConclusionFinally, we demonstrated that LINC02154 and our constructed risk signature could predict outcomes and have potential clinical value.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1

Fig. 4

40249_2023_1060_Article_IEq2.gif

40854_2023_451_Article_IEq5.gif

Fig. 4

Fig. 4

Fig. 3

Fig. 5

40854_2023_461_Article_IEq30.gif

Fig. 2

Fig. 2

Fig. 1

Fig. 1